A
Ark Biosciences
Biopharmaceutical company that is dedicated to the discovery and development
About Ark Biosciences
Ark Biosciences is a biotech startup headquartered in the Zhangjiang Hi-Tech Park of Shanghai, specializing in the discovery and development of innovative antiviral drugs targeting respiratory viruses. The company operates in the global pharmaceutical market, focusing on creating treatments for respiratory diseases. Ark Biosciences serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and research institutions. The business model revolves around the research and development (R&D) of new drugs, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the sale of these drugs, licensing agreements, and potential partnerships with larger pharmaceutical firms. The company is committed to advancing healthcare by addressing unmet medical needs in the respiratory virus field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Huangpu, China
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 42.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Jul 2022 | — | — | Qiming Venture Partners · Loyal Valley Capital · Oriza Holdings · Xiamen C&D Emerging Industry Equity Investment | ↗ |
| OtherOther financing | Jan 2021 | $0 | — | Dyee Capital · TPG · Decheng Capital · Hillhouse Capital | — |
Growth signals
Latest recorded traffic for Ark Biosciences is 1.4K monthly website visits, up 72.8% over the last three months. Ark Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
TF Capital
Morningside
Qiming Venture Partners
Yuansheng BioVenture
5Y Capital
Oriza Ventures
Series B and later6 investors entered at this stage
Loyal Valley Capital
Oriza Holdings
Xiamen C&D Emerging Industry Equity Investment- CFChina SME Development Fund
- FFFTZ Fund
- LFLongda Food
Other known investors5 additional known investors
Decheng Capital
Dyee Capital
Hillhouse Capital
TPG- WFWest Fountain Global Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ark Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ark Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.